

1 **Lipopolysaccharide preconditioning augments phagocytosis of malaria-parasitized red**
2 **blood cells through induced bone marrow-derived macrophages in the liver, thereby**
3 **increasing the murine survival after *Plasmodium yoelii* infection**

4

5 Takeshi Ono^a, Yoko Yamaguchi^a, Hiroyuki Nakashima^b, Masahiro Nakashima^b, Takuya
6 Ishikiriyama^b, Shuhji Seki^b, Manabu Kinoshita^{b,#}

7

8 ^aDepartment of Global Infectious Diseases and Tropical Medicine, , National Defense Medical
9 College, Tokorozawa, Saitama, JAPAN

10 ^bDepartment of Immunology and Microbiology, National Defense Medical College,
11 Tokorozawa, Saitama, JAPAN

12

13 Running Head: LPS preconditioning augments phagocytosis of malaria

14

15 #Corresponding author. Mailing address: Department of Immunology and Microbiology,
16 National Defense Medical College, 3-2 Namiki, Tokorozawa City, Saitama 359-8513 JAPAN.

17 E-mail: manabu@ndmc.ac.jp

18

19 **Abstract**

20 Malaria remains a grave concern for humans, as effective medical countermeasures for malaria
21 infection have yet to be developed. Phagocytic clearance of parasitized red blood cells (pRBCs)
22 by macrophages is an important front-line innate host defense against malaria infection. We
23 previously showed that repeated injections of low-dose lipopolysaccharide (LPS) prior to
24 bacterial infection, called LPS preconditioning, strongly augmented phagocytic/bactericidal
25 activity in murine macrophages. However, how LPS preconditioning prevents murine malaria
26 infection is unclear. We investigated the protective effects of LPS preconditioning against
27 lethal murine malaria infection, focusing on CD11b^{high} F4/80^{low} liver macrophages, which are
28 increased by LPS preconditioning. Mice were subjected to LPS preconditioning by
29 intraperitoneal injections of low-dose LPS for 3 consecutive days, and 24 h later, they were
30 intravenously infected with pRBCs of *Plasmodium yoelii* 17XL. LPS preconditioning
31 markedly increased the murine survival and reduced parasitemia, while it did not reduce TNF
32 secretions, only delaying the peak of plasma IFN- γ after malaria infection in mice. An *in vitro*
33 phagocytic clearance assay of pRBCs showed that the CD11b^{high} F4/80^{low} liver macrophages
34 of the LPS-preconditioned mice had significantly augmented phagocytic activity against
35 pRBCs. The adoptive transfer of CD11b^{high} F4/80^{low} liver macrophages from LPS-
36 preconditioned mice to control mice significantly improved the survival after malaria infection.
37 We conclude that LPS preconditioning stimulated CD11b^{high} F4/80^{low} liver macrophages to
38 augment the phagocytic clearance of pRBCs, which may play a central role in resistance against
39 malaria infection. LPS preconditioning may be an effective tool for preventing malaria
40 infection.

41

42 **Introduction**

43 According to the ‘World Malaria Report 2019’ from the World Health Organization (WHO),
44 malaria is one of the three major infectious diseases, along with acquired immune deficiency
45 syndrome (AIDS) and tuberculosis, and efforts are underway to eliminate it (1). However, an
46 increases in drug resistance to parasites and insecticide resistance to mosquitoes has threatened
47 to worsen the infection control of malaria, leading to a high mortality (2, 3). The development
48 of an effective malaria vaccine remains challenging (4). Therefore, there is an urgent need to
49 establish effective medical countermeasures, including preventative and mitigation efforts,
50 against severe malaria infection that do not rely on antimalaria drugs.

51 The augmentation of the host defense against malaria infections is important for
52 improving patient outcomes. If activation of the innate immunity is effective for eliminating
53 malaria parasites, a reduced malaria mortality can be expected, and instances of drug-resistant
54 malaria can be eliminated. However, previously reported methods of activating innate
55 immunity may also induce an enhanced inflammatory response in the hosts, resulting in organ
56 damage (5). Augmentation of the elimination of infected cells without enhancing the
57 inflammatory response may be an ideal medical countermeasure against malaria infection.

58 We recently reported that repeated low-dose LPS injection, termed LPS
59 preconditioning or LPS tolerance (6) (7), renders mice drastically resistant to bacterial infection,
60 as such LPS preconditioning potently reduces the host’s inflammatory response to bacterial
61 stimuli while markedly augmenting the host’s bactericidal activity (8). LPS preconditioning
62 increases the population of monocyte-derived macrophages in the liver and enhances their
63 phagocytosis and bactericidal activity.

64 The liver plays a crucial role in malaria infection in the initial phase. We therefore
65 attempted to use these attractive phenomena induced by LPS preconditioning as novel medical

66 countermeasures against malaria infection and investigated whether or not LPS
67 preconditioning can prevent severe malaria infection using a murine malaria infection model.
68

69 **Results**

70 *LPS preconditioning improved the mouse survival after lethal malaria infection*

71 LPS preconditioning was induced by intraperitoneal injections of 5, 50 or 500 µg/kg of LPS
72 for 3 consecutive days in mice, and 24 h after the last LPS injection, they were intravenously
73 infected with the GFP-expressing *Plasmodium yoelii* 17XL (PyLGFP) (5×10^4 pRBCs). This
74 dose of PyLGFP infection was lethal for non-treated control mice (Fig. 1A-C). However,
75 preconditioning with 5 µg/kg of LPS tended to prolong the murine survival time after PyLGFP
76 infection (Fig. 1A). Interestingly, preconditioning with 50 µg/kg of LPS showed a 20% survival
77 rate in PyLGFP-infected mice (Fig. 1B), and preconditioning with 500 µg/kg LPS resulted in
78 more than half of the infected mice surviving (60% survival, Fig. 1C), suggesting that LPS
79 preconditioning significantly increased the survival of PyLGFP-infected mice.

80

81 *LPS preconditioning reduced the growth of malaria in mice at 5 days after infection*

82 Next, we examined the effect of LPS preconditioning (5 or 500 µg/kg of LPS) on the growth
83 of PyLGFP in mice. Although no significant reduction was noted at 3 days, LPS
84 preconditioning with both 5 and 500 µg/kg LPS significantly reduced the parasitemia at 5 days
85 after infection (Fig. 2A, B). We confirmed the significant reduction in parasitemia by LPS
86 preconditioning using a flow cytometric analysis. LPS preconditioning with both 5 and 500
87 µg/kg LPS significantly reduced the proportion of GFP-positive RBCs, which indicated
88 PyLGFP-parasitized RBCs, at 5 days after infection (Fig. 2C, D). This suggested that LPS
89 preconditioning potently reduced growth of malaria in mice during the early phase of parasite
90 infection (at 5 days), resulting in an improved survival after infection.

91

92 *LPS preconditioning augmented the phagocytic clearance of pRBCs by $CD11b^{high}$ $F4/80^{low}$* 93 *macrophages in the murine liver*

94 We first examined the effect of LPS preconditioning on the phagocytic clearance of pRBCs in
95 the murine liver mononuclear cells (MNCs). Liver MNCs were obtained from the LPS-
96 preconditioned mice 24 h after the last LPS injection to use for the following examinations.
97 After co-culture with pRBCs for 16 h, the liver MNCs of the LPS-preconditioned mice (with
98 500 $\mu\text{g}/\text{kg}$ LPS) significantly reduced the number of pRBCs in the culture medium compared
99 with the control mice (Fig. 3A), suggesting that LPS preconditioning augmented the phagocytic
100 clearance of pRBCs by liver MNCs.

101 Next, we examined the phagocytic clearance of pRBCs by the $\text{CD11b}^{\text{high}} \text{F4/80}^{\text{low}}$ liver
102 macrophages, which are markedly increased by LPS preconditioning (8). We sorted the
103 $\text{CD11b}^{\text{high}} \text{F4/80}^{\text{low}}$ liver macrophages and other liver MNCs of the LPS-preconditioned mice
104 (with 500 $\mu\text{g}/\text{kg}$ LPS) and co-cultured these cells (5×10^5 cells) with pRBCs for 16 h. The
105 $\text{CD11b}^{\text{high}} \text{F4/80}^{\text{low}}$ liver macrophages of the LPS-preconditioned mice significantly reduced
106 the number of residual pRBCs in the culture medium compared with other MNC subsets in the
107 LPS-preconditioned mice (Fig. 3B), which subset however showed a significant reduction in
108 residual pRBCs compared to the whole liver MNCs of the control mice [Sorry, this is unclear:
109 please clarify the meaning of the highlighted text] (Fig. 3B). This suggested that LPS
110 preconditioning stimulated liver MNCs, particularly $\text{CD11b}^{\text{high}} \text{F4/80}^{\text{low}}$ liver macrophages,
111 encouraging them to augment the phagocytic clearance of pRBCs.

112

113 *Changes in the plasma cytokine levels after malaria infection in mice*

114 LPS preconditioning markedly reduces the TNF and $\text{IFN-}\gamma$ secretion in mice after bacterial
115 infection (8). We then examined these cytokine responses to malaria infection in the LPS-
116 preconditioned mice. Unlike bacterial infection, no significant difference in the plasma TNF
117 levels were observed after PyLGFP infection between the control and LPS-preconditioned
118 mice with 5 or 500 $\mu\text{g}/\text{kg}$ LPS (Fig. 4A, B). The plasma $\text{IFN-}\gamma$ levels peaked at 3 days after

119 PyLGFP infection in control mice, whereas LPS preconditioning with 5 and 500 $\mu\text{g}/\text{kg}$ LPS
120 both delayed those IFN- γ peaks, which instead peaked at 5 days after infection (Fig. 4C, D).

121

122 *Pathological observation of the murine liver 5 days after malaria infection*

123 In the pathological examination of hematoxylin-eosin (H.E.) staining, RBC-phagocytosis by
124 macrophages was markedly observed in the liver of LPS-preconditioned mice (with 500 $\mu\text{g}/\text{kg}$
125 LPS) compared with control mice (Fig. 5). To confirm the phagocytosis of PyLGFP-parasitized
126 RBCs in the murine liver, we performed the immunohistochemical staining of GFP in the liver
127 of PyLGFP-infected mice. Consistent with H.E. staining, positive staining of GFP in liver
128 macrophages, which indicates phagocytosis of pRBCs, was also obviously observed in the
129 LPS-preconditioned mice compared with the control mice (Fig. 6).

130

131 *Adoptive transfer of CD11b^{high} F4/80^{low} liver macrophages from LPS-preconditioned mice 132 induced resistance to malaria infection in control mice*

133 To confirm the effect of CD11b^{high} F4/80^{low} liver macrophages, which are induced by LPS
134 preconditioning, on the resistance to rodent malaria infection, we performed the adoptive
135 transfer of CD11b^{high} F4/80^{low} liver macrophages from the LPS-preconditioned mice (with 500
136 $\mu\text{g}/\text{kg}$ LPS) to control mice and then infected these mice with PyLGFP. Adoptive transfer of
137 CD11b^{high} F4/80^{low} liver macrophages from the LPS-preconditioned mice to the control mice
138 significantly prolonged the survival time after malaria infection, although the adoptive transfer
139 of other liver MNC subset cells did not improve the survival (Fig. 7A). However, there were
140 no significant changes in plasma IFN- γ or TNF levels after PyLGFP infection among the three
141 mouse groups (Fig. 7B, C). These results support the notion that CD11b^{high} F4/80^{low} liver
142 macrophages, which are a key fraction in the induction of LPS preconditioning, play a major
143 role in resistance to malaria infection.

144 **Discussion**

145 LPS preconditioning significantly augmented the phagocytic clearance of PyLGFP-parasitized
146 RBCs by CD11b^{high} F4/80^{low} liver macrophages (Fig. 3B), which are monocyte-derived
147 macrophages increased by LPS preconditioning (8), resulting in the improvement of the murine
148 survival after PyLGFP infection (Fig. 1). We confirmed the beneficial effect of CD11b^{high}
149 F4/80^{low} liver macrophages on the survival of PyLGFP-infected mice through the adoptive
150 transfer of these macrophages (Fig. 7). LPS preconditioning effectively prevented rodent
151 malaria infection without enhancing the proinflammatory cytokine responses to malaria
152 infection (Fig. 4). This approach may be an attractive medical countermeasure for malaria
153 infection.

154 Although the T cell-mediated immune response to initial malaria infection is well
155 described, other immune cells, such as dendritic cells and monocytes/macrophages, have been
156 shown to modulate immune activation and the severity of disease as well (9, 10). However,
157 mice lacking tissue-resident macrophages experience increased malaria-related complications,
158 such as disruptions in the blood-brain barrier, increased vascular permeability in the liver, and
159 increased accumulation of hemozoin pigment in the lung (11). These studies imply a critical
160 role for macrophages in the initial response to malaria infection. The liver stage of malaria is
161 the first phase of infection in the hosts, and the liver-resident macrophages, namely Kupffer
162 cells, play important roles in ameliorating the severity of malaria infection and preventing
163 parasite release into the blood circulation (12).

164 LPS preconditioning may stimulate the CD11b^{high} F4/80^{low} liver macrophages to
165 augment phagocytic activity against bacteria, which are external pathogens (8). These
166 monocyte-derived macrophages alter their phagocytic phenotype, like Kupffer cells, as LPS
167 preconditioning strongly upregulates their Fc- γ receptor I (Fc γ RI) expression (8), which is a
168 critical Fc γ R involved in phagocytosis (13). Fc γ Rs are also closely involved in opsonization,

169 which is the process of antibodies binding to the pathogen and enabling ingestion and
170 elimination by macrophages. However, unlike common bacteria (*Escherichia coli*,
171 *Pseudomonas aeruginosa*), infected malaria parasitizes host RBCs. To eliminate malaria
172 infection, macrophages must effectively phagocytose malaria-parasitized RBCs. Interestingly, a
173 recent study reported that splenic red pulp macrophages, which are distinct from monocyte-
174 derived macrophages, effectively phagocytose IgG-opsonized RBCs using FcγRs, most
175 notably FcγRI (13). The CD11b^{high} F4/80^{low} liver macrophages induced by LPS
176 preconditioning, which may show an increased FcγRI expression on their surface albeit
177 monocyte-derived ones [Sorry, this is unclear: please clarify the meaning of the highlighted
178 text], may demonstrate enhanced phagocytosis of malaria-parasitized RBCs through
179 upregulated FcγRI.

180 LPS preconditioning drastically reduces proinflammatory cytokine responses, such as
181 TNF and IFN-γ, to bacterial stimuli (7, 8). However, LPS preconditioning did not decrease
182 TNF secretion after PyLGFP infection in mice (Fig. 4). Macrophages do not robustly produce
183 proinflammatory cytokines, including TNF, during the early phase of malaria infection because
184 phagosomal acidification of malaria-parasitized RBCs prevents macrophages from producing
185 proinflammatory cytokines (14). Nevertheless, malaria-parasitized RBCs opsonized by
186 immune serum increase TNF secretion from macrophages, suggesting that TNF production by
187 macrophages is closely involved in their FcγR-mediated phagocytosis of malaria (15). Unlike
188 bacterial infection, which involves an external pathogen, macrophages do not produce large
189 amounts of TNF due to malaria infection; macrophage-produced TNF may be necessary for
190 effective phagocytic elimination of parasitized RBCs. In the current study, sustained (albeit a
191 low amounts of) TNF secretion may have helped enhance the elimination of malaria-
192 parasitized RBCs by macrophages induced by LPS preconditioning, resulting in an
193 improvement in murine malaria infection.

194 IFN- γ is the most powerful proinflammatory cytokine. An IFN- γ -induced tissue
195 inflammatory reaction is required for effective bacterial elimination by the host; however, an
196 IFN- γ -induced exaggerated inflammatory response can also cause sepsis and multi-organ
197 injuries (16). LPS preconditioning did not reduce the plasma peak of IFN- γ but did delay its
198 peak from 3 days to 5 days after PyLGFP infection (Fig. 4). In murine malaria infection,
199 neutralizing IFN- γ prolonged lethal rodent malaria infection but did not reduce parasitemia
200 (17). Similar to sepsis, the presence of proinflammatory cytokines, including IFN- γ , during
201 acute malaria infection may be related to signs of severe malaria pathogenesis (18), IFN- γ
202 secretion may not (at least negatively) affect parasitemia in mice. However, the rationale of
203 this delayed peak of IFN- γ induced by LPS preconditioning should be investigated further in a
204 future study.

205 In conclusion, LPS preconditioning rendered mice resistant to rodent malaria infection.
206 CD11b^{high} F4/80^{low} liver macrophages that are induced by LPS preconditioning enhance the
207 phagocytic clearance of parasitized RBCs, thereby improving the survival in malaria-infected
208 mice.

209 **Materials and Methods**

210 The Ethics Committee of Animal Care and Experimentation in National Defense Medical
211 College Japan approved all requests for animals and the intended procedures of the present
212 study (Permission number:18025).

213

214 *Animals and reagents*

215 Male C57BL/6 mice (8 weeks old, body weight 20 g) were purchased from Japan SLC
216 (Hamamatsu, Japan) and used for this study. LPS (*E. coli* 0111:B4) was purchased from Sigma-
217 Aldrich (St. Louis, MO, USA) to use for LPS preconditioning. The *P. yoelii* 17XL lethal strain
218 has been kept in our laboratory as described elsewhere (19). We created a stable GFP-
219 expressing *P. yoelii* 17XL (PyLGFP) by transfection of an uncloned population of *P. yoelii*
220 17XL parasites with the vector pL0016, as described previously (20, 21).

221 We obtained pRBCs of PyLGFP from donor mice after intravenous (i.v.) inoculation
222 with a frozen stock of parasites. After i.v. injection of PyLGFP, we checked the parasitemia of
223 the donor mice daily. Thereafter, the pRBCs of PyLGFP were obtained at the proliferation
224 phase of parasitemia for use in the current experiment (parasite rates of PyLGFP were 10%-
225 15% of RBCs).

226

227 *Infection of rodent malaria (PyLGFP) in mice*

228 After obtaining pRBCs of PyLGFP from the donor mice, 2.5×10^5 pRBCs/mL with 0.2 mL
229 RPMI1640 medium were i.v. injected into recipient mice 24 h after the last injection of LPS
230 (LPS-preconditioned mice). The percentage of pRBCs in the recipient mice was monitored by
231 thin tail blood smears stained with Giemsa stain. The murine survival was monitored every day.

232

233 *Induction of in vivo LPS preconditioning*

234 LPS preconditioning was induced in mice by an intraperitoneal (i.p.) injection of 5, 50, or 500
235 $\mu\text{g}/\text{kg}$ of LPS (dissolved in 0.5 mL saline) once daily for three times, as we previously
236 described (8). Control mice were similarly i.p. injected with saline (0.5 mL) three times.

237

238 *Analyses of PyLGFP-parasitized RBCs using flow cytometry*

239 RBCs were obtained from the PyLGFP-infected mice at five days after infection. Percentages
240 of GFP-positive RBCs were evaluated as FITC intensity using flow cytometer (ACEA
241 Biosciences, San Diego, CA, USA). After gating RBCs, GFP-positive RBCs were detected as
242 FITC-positive.

243

244 *Isolation of liver MNCs from mice*

245 Liver MNCs, including macrophages, were obtained from mice as described elsewhere (22).
246 In brief, under deep isoflurane anesthesia, the liver was removed and minced with scissors.
247 After shaking with 10 mL of Hank's balanced salt solution containing 0.05% collagenase (Type
248 IV; Sigma-Aldrich) for 20 min at 37 °C, liver specimens were filtered through mesh, suspended
249 in 33% Percoll solution (Sigma-Aldrich) containing 10 U/mL heparin, and centrifuged for 15
250 min at $500 \times g$ at room temperature. After lysing RBCs, the remaining cells were washed twice
251 to obtain the liver MNCs.

252

253 *Sorting CD11b^{high} F4/80^{low} liver macrophages*

254 LPS preconditioning increases the number of CD11b^{high} F4/80^{low} macrophages in the murine
255 liver and potently augments their bactericidal activity (8). To sort this CD11b^{high} F4/80^{low}
256 subset from the liver MNCs, obtained liver MNCs were stained with FITC-conjugated anti-
257 F4/80 monoclonal antibody (mAb) (clone BM8; eBioscience, , San Diego, CA, USA), PE-
258 conjugated anti-CD11b mAb (clone M1/70, eBioscience), and APC-conjugated anti-CD45

259 mAb (clone 30-F11, eBioscience). Thereafter, CD11b^{high} F4/80^{low} CD45⁺ cells were sorted
260 using a Sony SH800 cell sorter (Sony, Tokyo, Japan) (Supplemental Fig. 1). We also sorted
261 CD45⁺ MNCs except for the CD11b^{high} F4/80^{low} cell subset from the liver MNCs using a cell
262 sorter.

263

264 *In vitro phagocytic clearance of PyLGFP-parasitized RBCs by liver MNCs or CD11b^{high}*
265 *F4/80^{low} liver macrophages*

266 To examine the pRBC phagocytic clearance by liver MNCs, liver MNCs (5×10^5 cells/200 μ L)
267 were obtained from LPS-preconditioned mice 24 h after the last LPS injection or control non-
268 treated mice and then cocultured with 1×10^7 pRBCs of PyLGFP (PyLGFP parasite rates were
269 10%-15% of RBCs) in antibiotic-free RPMI1640 medium for 16 h. The CD11b^{high} F4/80^{low}
270 liver macrophages or other CD45⁺ liver MNCs were sorted from the liver MNCs in mice 24 h
271 after the last LPS injection. Thereafter, these sorted cells (5×10^5 cells/200 μ L) were similarly
272 cocultured with 1×10^7 pRBCs for 16 h. After coculture for 16 h, the total RBC count in the
273 culture medium was measured, and the proportion of pRBCs was counted in the smear stained
274 with Giemsa stain. We then obtained the number of residual PyLGFP-parasitized RBCs in the
275 culture medium.

276

277 *Adoptive transfer of CD11b^{high} F4/80^{low} liver macrophages from the LPS-preconditioned mice*
278 *to control mice*

279 To examine the effect of CD11b^{high} F4/80^{low} liver macrophages that are induced by LPS
280 preconditioning on the rodent malaria infection, CD11b^{high} F4/80^{low} CD45⁺ cells were sorted
281 from the liver MNCs of the LPS-preconditioned mice using the cell sorter. The CD45⁺ liver
282 MNCs except CD11b^{high} F4/80^{low} subset were also sorted from the liver MNCs of the LPS-
283 preconditioned mice. Thereafter, these sorted cells (1×10^6 cells /200 μ L PBS) were adoptively

284 transferred into the recipient normal mice, and 2.5×10^5 of pRBCs (with 0.2 mL RPMI1640
285 medium) were subsequently i.v. injected into recipient mice.

286

287 *Measurements of plasma cytokines in mice*

288 Blood samples were obtained from the mice via submandibular bleeding using 5-mm
289 GoldenRod Animal Lancets (MEDIpoinc Inc., Mineola, NY, USA). Plasma TNF and IFN- γ
290 levels were measured using their respective ELISA kits (BD OptEIA™; BD Biosciences, San
291 Diego, CA, USA).

292

293 *Pathological analyses of the liver in the rodent malaria-infected mice*

294 Under deep isoflurane anesthesia, the livers were removed from the mice 5 days after PyLGFP
295 infection. Isolated liver samples were fixed in 4% formaldehyde, embedded in paraffin and
296 sectioned at a thickness of 3 μ m. The sections were subjected to H.E. staining or an
297 immunohistochemical analysis. Regarding immunohistochemical staining of GFP, anti-GFP
298 polyclonal antibody (1:500; MBL, Nagoya, Japan) was used as the primary antibody, HRP-
299 labeled anti-rabbit IgG antibody (Nichirei, Tokyo, Japan) was used as the secondary antibody,
300 and diaminobenzidine was used for the colorimetric reaction. These procedures were
301 outsourced to LSI Medience (Tokyo, Japan).

302

303 *Statistical analyses*

304 Statistical analyses were performed using the GraphPad Prism software program, version 8
305 (GraphPad Software, San Diego, CA, USA). A two-way analysis of variance (ANOVA)
306 followed by Bonferroni's post-hoc comparison test was used to assess the percentage of
307 parasitemia. A repeated-measure ANOVA was used to compare the plasma cytokine levels
308 between control and LPS-preconditioned mice. The data were the means \pm standard error (SE)

309 and were analyzed using either Student's *t*-test or Mann–Whitney U test. $p < 0.05$ was
310 considered statistically significant.


311

312 **Acknowledgments**

313 This work was supported by JSPS KAKENHI Grant Number 19K07493 (T.O. and M.K.).

314

315




316

317

318 **FIG 1** The survival after rodent malaria infection in LPS-preconditioned mice. LPS
319 preconditioning was induced in mice with i.p. injection of 5 (A), 50 (B), or 500 (C) µg/kg LPS
320 for 3 consecutive days, and 24 h after the last LPS injection, the mice were i.v. infected with 5
321 $\times 10^4$ pRBCs of PyLGFP. Ten mice in each group. ** $p < 0.01$, * $p < 0.05$ vs. control.

322

323



324

325 **FIG 2** The effects of LPS preconditioning on the parasitemia after *Py*LGFP infection in mice.

326 Mice were similarly subjected to LPS preconditioning with i.p. injection of 5 $\mu\text{g/kg}$ or 500


327 $\mu\text{g/kg}$ LPS, and 24 h later, they were i.v. infected with *Py*LGFP-parasitized RBCs. Parasitemia

328 at days 3 and 5 post-infection was measured by Giemsa stain (A, B). The proportion of

329 *Py*LGFP-parasitized RBCs was also evaluated at day 5 as the FITC intensity using a flow

330 cytometer (C, D). Data are the means \pm SE from 10 mice in each group. * $p < 0.05$ vs. control.


331



332

333 **FIG 3** An *in vitro* phagocytosis assay. Liver MNCs (A) or sorted CD11b^{high} F4/80^{low} liver
334 macrophages (B) were obtained from the LPS (500 µg/kg)-preconditioned mice and cocultured
335 with PyLGFP-parasitized RBCs for 16 h. Thereafter, residual pRBCs were counted. Data are
336 the means ± SE from 5 mice in each group. ***p < 0.0001, **p < 0.01, *p < 0.05.

337



338

339 **FIG 4** Changes in the plasma cytokine levels after PyLGFP infection in LPS-preconditioned

340 mice and control mice. LPS-preconditioned mice with 5 $\mu\text{g/kg}$ LPS (A, C) or 500 $\mu\text{g/kg}$ LPS

341 (B, D) and control mice were i.v. infected with 5×10^4 PyLGFP-parasitized RBCs to examine


342 the plasma IFN- γ and TNF. Data are the means \pm SE from 10 mice in each group. **p < 0.01,

343 *p < 0.05 vs. control (at the same time point).


344

345

Control



LPS preconditioning



x400


346

347 **FIG 5** Results of a pathological examination of the liver after PyLGFP infection. Liver sections
348 of LPS (500 $\mu\text{g}/\text{kg}$)-preconditioned mice and control mice were stained with H.E. Data are
349 representative of three mice in each group with similar results. Right columns are magnified
350 images of the yellow squares in the left columns. Arrowheads indicate RBC-phagocytosed
351 macrophages.


352

353

Control



LPS preconditioning



x400

Anti GFP Ab

354

355 **FIG 6** Results of an immunohistochemical analysis of pRBC-phagocytosed macrophages in

356 the liver. Liver sections of LPS (500 μ g/kg)-preconditioned mice and control mice were stained


357 with anti-GFP Ab, as described in the Materials and methods. Arrowheads indicate cells with

358 GFP-positive staining, which are pRBCs. Data are representative of three mice in each group

359 with similar results. Right columns are magnified images of the squares in the left columns.

360

361



362

363 **FIG 7** Adoptive transfer of CD11b^{high} F4/80^{low} liver macrophages from LPS-preconditioned
364 mice to control mice. CD11b^{high} F4/80^{low} liver macrophages and CD45⁺ liver MNCs (except
365 for the CD11b^{high} F4/80^{low} subset) were obtained from the LPS-preconditioned mice (with 500
366 μ g/kg LPS) and transferred to control mice. Thereafter, mice were i.v. infected with PyLGFP-
367 parasitized RBCs to monitor their survival (A), plasma IFN- γ (B), and TNF (C) levels. The
368 number of mice in each group is indicated in the panel. * p < 0.01 vs. control mice and p < 0.05
369 vs. mice with transferred CD45⁺ liver MNCs except for CD11b^{high} F4/80^{low} cells.

370

371 **References**

- 372 1. World Health Organization. 2019. World malaria report 2019.
- 373 2. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. 2002. Epidemiology of
374 drug-resistant malaria. *Lancet Infect Dis* 2:209–218.
- 375 3. Blasco B, Leroy D, Fidock DA. 2017. Antimalarial drug resistance: linking *Plasmodium*
376 *falciparum* parasite biology to the clinic. *Nat Med* 23:917–928.
- 377 4. Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC. 2018. Malaria vaccines: recent
378 advances and new horizons. *Cell Host Microbe*.
- 379 5. Kinoshita M, Seki S, Ono S, Shinomiya N, Hiraide H. 2004. Paradoxical effect of IL-18
380 therapy on the severe and mild *Escherichia coli* infections in burn-injured mice. *Ann Surg*
381 240:313–320.
- 382 6. Hato T, Winfree S, Kalakeche R, Dube S, Kumar R, Yoshimoto M, Plotkin Z, Dagher PC.
383 2015. The macrophage mediates the renoprotective effects of endotoxin preconditioning.
384 *J Am Soc Nephrol* 26:1347–1362.
- 385 7. Biswas SK, Lopez-Collazo E. 2009. Endotoxin tolerance: new mechanisms, molecules
386 and clinical significance. *Trends Immunol* 30:475–487.
- 387 8. Kinoshita M, Miyazaki H, Nakashima H, Nakashima M, Nishikawa M, Ishikiriya T,
388 Kato S, Iwaya K, Hiroi S, Shinomiya N, Seki S. 2017. In vivo Lipopolysaccharide
389 Tolerance Recruits CD11b⁺ Macrophages to the Liver with Enhanced Bactericidal
390 Activity and Low Tumor Necrosis Factor-Releasing Capability, Resulting in Drastic
391 Resistance to Lethal Septicemia. *J Innate Immun* 9:493–510.
- 392 9. Hisaeda H, Yasutomo K, Himeno K. 2005. Malaria: immune evasion by parasites. *Int J*
393 *Biochem Cell Biol* 37:700–706.
- 394 10. Hu W-C. 2013. Human immune responses to *Plasmodium falciparum* infection: molecular
395 evidence for a suboptimal TH α β and TH17 bias over ideal and effective traditional TH1

- 396 immune response. *Malar J* 12:392.
- 397 11. Gupta P, Lai SM, Sheng J, Tetlak P, Balachander A, Claser C, Rénia L, Karjalainen K,
398 Ruedl C. 2016. Tissue-Resident CD169(+) Macrophages Form a Crucial Front Line
399 against Plasmodium Infection. *Cell Rep* 16:1749–1761.
- 400 12. Ozarslan N, Robinson JF, Gaw SL. 2019. Circulating Monocytes, Tissue Macrophages,
401 and Malaria. *J Trop Med* 2019:3720838.
- 402 13. Nagelkerke SQ, Bruggeman CW, den Haan JMM, Mul EPJ, van den Berg TK, van
403 Bruggen R, Kuijpers TW. 2018. Red pulp macrophages in the human spleen are a distinct
404 cell population with a unique expression of Fc- γ receptors. *Blood Adv* 2:941–953.
- 405 14. Wu X, Gowda NM, Gowda DC. 2015. Phagosomal Acidification Prevents Macrophage
406 Inflammatory Cytokine Production to Malaria, and Dendritic Cells Are the Major Source
407 at the Early Stages of Infection: IMPLICATION FOR MALARIA PROTECTIVE
408 IMMUNITY DEVELOPMENT. *J Biol Chem* 290:23135–23147.
- 409 15. Zhou J, Ludlow LE, Hasang W, Rogerson SJ, Jaworowski A. 2012. Opsonization of
410 malaria-infected erythrocytes activates the inflammasome and enhances inflammatory
411 cytokine secretion by human macrophages. *Malar J* 11:343.
- 412 16. Kinoshita M, Miyazaki H, Ono S, Seki S. 2013. Immunoenhancing therapy with
413 interleukin-18 against bacterial infection in immunocompromised hosts after severe
414 surgical stress. *J Leukoc Biol* 93:689–698.
- 415 17. Yoshimoto T, Takahama Y, Wang CR, Yoneto T, Waki S, Nariuchi H. 1998. A
416 pathogenic role of IL-12 in blood-stage murine malaria lethal strain *Plasmodium berghei*
417 NK65 infection. *J Immunol* 160:5500–5505.
- 418 18. Clark IA, Budd AC, Alleva LM, Cowden WB. 2006. Human malarial disease: a
419 consequence of inflammatory cytokine release. *Malar J* 5:85.
- 420 19. Ono T, Yamaguchi Y, Oguma T, Takayama E, Takashima Y, Tadakuma T, Miyahira Y.

- 421 2012. Actively induced antigen-specific CD8(+) T cells by epitope-bearing parasite pre-
422 infection but not prime/boost virus vector vaccination could ameliorate the course of
423 *Plasmodium yoelii* blood-stage infection. *Vaccine* 30:6270–6278.
- 424 20. Franke-Fayard B, Trueman H, Ramesar J, Mendoza J, van der Keur M, van der Linden R,
425 Sinden RE, Waters AP, Janse CJ. 2004. A *Plasmodium berghei* reference line that
426 constitutively expresses GFP at a high level throughout the complete life cycle. *Mol*
427 *Biochem Parasitol* 137:23–33.
- 428 21. Ono T, Tadakuma T, Rodriguez A. 2007. *Plasmodium yoelii yoelii* 17XNL constitutively
429 expressing GFP throughout the life cycle. *Exp Parasitol* 115:310–313.
- 430 22. Kinoshita M, Uchida T, Sato A, Nakashima M, Nakashima H, Shono S, Habu Y, Miyazaki
431 H, Hiroi S, Seki S. 2010. Characterization of two F4/80-positive Kupffer cell subsets by
432 their function and phenotype in mice. *J Hepatol* 53:903–910.
- 433